News and Announcements
Xeophin Pty Ltd announces the launch of it’s Pre ICO & ICO raise using Blockchain technologies in Europe and Asia
- Published June 26, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Xeophin, a biotech company, is committed to the research, development and commercialisation of new and novel medical treatments
- Have appointed Dr.Goran Ando as Chairman of its Clinical Advisory Committee
- Have appointed ex-Chairman of Novo Nordisk, Dr.Goran Ando, as Chairman of its Clinical Advisory Committee
Xeophin is focused on imunomodulating technologies and is committed to the research, development and commercialisation of new and novel medical treatments, in a number of high growth therapeutic areas such as inflammation.
Xeophin has also secured the appointment of Dr.Goran Ando as Chairman of its Clinical Advisory Committee.
Dr Ando has held the position of Chairman of Novo Nordisk A /S since 2013 and has been on the board since 2005, being re-elected several times throughout his tenure. Dr Ando is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. Dr Ando serves as chairman of the board of Symphogen A /S, Denmark and as a board member of Novo Holdings A /S, Denmark, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, and ICMEC, US. Dr Ando also serves as a Senior Advisor to Essex Woodlands Healthcare Partners, UK.
About Xeophin
Xeophin Pty Ltd is a Biotech Company with a focus on imunomodulating technologies, and is committed to the research, development and commercialisation of new and novel medical treatments, in a number of high growth therapeutic areas such as inflammation.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
